Pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects
| Autor: | Thomas Marbury, Zhu Y, Ticho B, Tenhoor C, Suzanne K. Swan, Zhaoyang Li |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty Cmax Renal function Adenosine A1 Receptor Antagonists Gastroenterology Excretion Pharmacokinetics Internal medicine medicine Humans Pharmacology (medical) Renal Insufficiency Aged Aged 80 and over Pharmacology business.industry Middle Aged medicine.disease TONAPOFYLLINE Xanthines Pharmacodynamics Kaliuresis Heart failure Female business |
| Zdroj: | Int. Journal of Clinical Pharmacology and Therapeutics. 49:563-570 |
| ISSN: | 0946-1965 |
| DOI: | 10.5414/cp201518 |
| Popis: | OBJECTIVE The study was conducted to characterize the pharmacokinetics and pharmacodynamics of tonapofylline in subjects with severe renal impairment and in elderly subjects. METHOD Subjects with severe renal impairment were matched demographically with healthy subjects. Elderly subjects with normal renal function for their ages were also enrolled. All subjects (n = 8 per group) received a single intravenous administration of tonapofylline at 1 mg/kg. RESULTS The pharmacokinetics of tonapofylline was not significantly different in subjects with severe renal impairment, or in elderly subjects, as compared to healthy subjects. Among all pharmacokinetic parameters, the only statistically significant difference was observed for Cmax between the healthy and the severe renal impairment groups, which was 21% and considered clinically insignificant. Pharmacodynamic assessment demonstrated the natriuretic effects of tonapofylline across groups, with little accompanying kaliuresis. No change in renal function occurred after single dose of tonapofylline, despite substantial increases in excretion of urinary sodium. Single 1 mg/kg intravenous administration of tonapofylline was generally safe. CONCLUSION The pharmacokinetics of tonapofylline in subjects with severe renal impairment and elderly subjects with normal renal function for age is similar to that in healthy subjects. It has been demonstrated in all groups that tonapofylline has natriuretic effects and is able to maintain renal function, which can be beneficial to patients with congestive heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|